Who are DRV/r's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): saquinavir/ritonavir, Antiretroviral therapy, Telzir®, Ritonavir (heat-stable), Nelfinavir and Omeprazole, Saquinavir (Invirase®).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/drv-r.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DRV/r — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DRV/r (DRV/r) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor (boosted). Area: Infectious Disease.

marketed Protease inhibitor (boosted) HIV protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

DRV/r (DRV/r) — Community Research Initiative of New England. DRV/r is a combination of darunavir (a protease inhibitor) boosted with ritonavir (a pharmacokinetic enhancer) that blocks HIV protease to prevent viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DRV/r TARGET	DRV/r	Community Research Initiative of New England	marketed	Protease inhibitor (boosted)	HIV protease
saquinavir/ritonavir	saquinavir/ritonavir	International Antiviral Therapy Evaluation Center	marketed	HIV protease inhibitor	HIV protease
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Telzir®	Telzir®	ViiV Healthcare	marketed	HIV protease inhibitor	HIV protease
Ritonavir (heat-stable)	Ritonavir (heat-stable)	Bristol-Myers Squibb	marketed	HIV protease inhibitor	HIV protease
Nelfinavir and Omeprazole	Nelfinavir and Omeprazole	Pfizer	marketed	HIV protease inhibitor + proton pump inhibitor combination	HIV protease (nelfinavir); H+/K+-ATPase proton pump (omeprazole)
Saquinavir (Invirase®)	Saquinavir (Invirase®)	Royal Free Hampstead NHS Trust	marketed	HIV protease inhibitor	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor (boosted) class)

Community Research Initiative of New England · 1 drug in this class
Juan A. Arnaiz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DRV/r — Competitive Intelligence Brief. https://druglandscape.com/ci/drv-r. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing